Dianthus Therapeutics (DNTH) Cash & Equivalents (2017 - 2025)

Dianthus Therapeutics' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $50.2 million for Q4 2025.

• On a quarterly basis, Cash & Equivalents rose 128.96% year-over-year to $50.2 million in Q4 2025; TTM through Dec 2025 was $50.2 million, a 128.96% increase from a year earlier, with the FY2025 full-year figure at $50.2 million, up 128.96% from the prior year.
• Cash & Equivalents retreated to $50.2 million in Q4 2025 per DNTH's latest filing, from $55.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $329.7 million in Q1 2024 and bottomed at $10.1 million in Q1 2025.
• The 5-year median for Cash & Equivalents is $52.5 million (2022), against an average of $92.7 million.
• Across the five-year window, Cash & Equivalents jumped 1320.49% in 2024 and tumbled 96.93% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $131.6 million in 2021, then sank by 88.33% to $15.4 million in 2022, then soared by 761.21% to $132.3 million in 2023, then sank by 83.42% to $21.9 million in 2024, then surged by 128.96% to $50.2 million in 2025.
• Per Business Quant, the three latest DNTH Cash & Equivalents figures stand at $50.2 million (Q4 2025), $55.0 million (Q3 2025), and $13.2 million (Q2 2025).